BIOPROSPECT CONFUSED OVER RIGHTS DISPUTE

BIOPROSPECT CONFUSED OVER RIGHTS DISPUTE

BIOPROSPECT Limited (BPO) chief operating officer Peter May (pictured) has admitted relations with partner Solagran Limited (SLA) are ‘strained’, with what he calls a lack of transparency over an alleged rights dispute.

While it has been more than a week since Solagran announced to the ASX the companies were in dispute, BioProspect is yet to receive clarification over what the dispute is exactly about.

BioProspect is a natural health products developer that is currently in the commercialisation phase with its Bioeffectives range.

“We have development agreements with Solagran that are still in operation and there’s been no reference from Solagran that they have been breached,” says May.

“I guess if you’re exchanging letters rather than sitting at a table then it’s fair to say the relationship is strained. We’re trying to set up a meeting but it’s not like we can knock on the door cold – there needs to be discussions at a senior level.

“We have products that involve Solagran products and we knew where that market was going. We were in the process of commercialisation, going from evaluation to the negotiation phase for supply agreements, but then Solagran went and made that announcement.”

On June 28 Solagran representative Kamran Shamsi resigned from the board of BioProspect, as SLA announced the two companies were in dispute over intellectual property rights.

“We sent a letter asking for clarification and we still haven’t received a response from them,” says May.

Solagran CEO Branko Jovanovic was hesitant to speak on the issue and could not give a timeframe for when an explanation will come.

“I can tell you we have no further comment at this time and we will make an announcement to the market in due course,” he says.

Subscribe Now!
Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

HMC Capital enters private credit market with $127.5m purchase of Payton Capital

HMC Capital enters private credit market with $127.5m purchase of Payton Capital

After more than a year of due diligence and amidst plans to lift it...

Cost of living elevates salaries and perks as key drivers of employee retention in 2024

Cost of living elevates salaries and perks as key drivers of employee retention in 2024

The cost of living is making salaries and perks just as important a...

Enterprise roll-out "one of the biggest launches in Canva's history" as ARR hits $2.2b

Enterprise roll-out "one of the biggest launches in Canva's history" as ARR hits $2.2b

Sydney-headquartered graphic design and visualisation tool giant Ca...

The Star unsuitable to hold a casino licence, final Bell Inquiry submissions claim

The Star unsuitable to hold a casino licence, final Bell Inquiry submissions claim

The Star Entertainment Group (ASX: SGR) has been declared unsuitabl...